[Correspondence] Dacomitinib in NSCLC: a positive trial with little clinical impact

I have read with great interest the report of the ARCHER 1050 trial by Li-Yong Wu and colleagues.1 The findings showed the superiority of dacomitinib over gefitinib in terms of progression-free survival in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) with the common EGFR mutation. The results were initially presented at the 2017 ASCO Annual Meeting and, at that time, it was the first time that a second-generation EGFR tyrosine kinase inhibitor (TKI) showed a clear and clinically significant improvement in terms of progression-free survival (14·7 months [95% CI 11·1–16·6] with dacomitinib vs 9·2 months [9·1–11·0] with gefitinib).

http://ift.tt/2zLPUJ8